Get the Stockscreener App
60.72
1.10%
+0.66
After Hours:
60.72
Vaxcyte Inc stock is currently priced at $60.72, with a 24-hour trading volume of 584.99K.
It has seen a +1.10% increased in the last 24 hours and a -9.94% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $59.42 pivot point. If it approaches the $60.73 resistance level, significant changes may occur.
Previous Close:
$60.06
Open:
$60.32
24h Volume:
584.99K
Market Cap:
$6.49B
Revenue:
-
Net Income/Loss:
$-402.27M
P/E Ratio:
-15.67
EPS:
-3.876
Net Cash Flow:
$-364.67M
1W Performance:
-0.18%
1M Performance:
-9.94%
6M Performance:
+25.79%
1Y Performance:
+44.57%
1D Range:
$59.41
$60.95
52W Range:
$41.57
$82.04
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650 837 0111
Address
353 Hatch Drive, Foster City, CA
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
GlobeNewswire Inc.
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
Zacks Investment Research
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Vaxcyte Inc Stock (PCVX) Financials Data
Vaxcyte Inc (PCVX) Net Income 2024
PCVX net income (TTM) was -$402.27 million for the quarter ending December 31, 2023, a -80.00% decrease year-over-year.
Vaxcyte Inc (PCVX) Cash Flow 2024
PCVX recorded a free cash flow (TTM) of -$364.67 million for the quarter ending December 31, 2023, a -106.67% decrease year-over-year.
Vaxcyte Inc (PCVX) Earnings per Share 2024
PCVX earnings per share (TTM) was -$4.7519 for the quarter ending December 31, 2023, a -38.54% decline year-over-year.
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 23 '24 |
Option Exercise |
1.79 |
15,000 |
26,850 |
492,847 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 23 '24 |
Sale |
61.92 |
15,000 |
928,845 |
477,847 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 18 '24 |
Option Exercise |
5.35 |
8,000 |
42,800 |
103,679 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 18 '24 |
Sale |
61.27 |
8,000 |
490,199 |
95,679 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Apr 17 '24 |
Option Exercise |
5.35 |
3,551 |
18,998 |
221,840 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Apr 01 '24 |
Option Exercise |
21.41 |
1,667 |
35,690 |
32,264 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Apr 01 '24 |
Sale |
66.69 |
3,000 |
200,066 |
218,289 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 01 '24 |
Sale |
66.71 |
2,616 |
174,502 |
147,362 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Apr 01 '24 |
Sale |
66.73 |
1,667 |
111,234 |
30,597 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Mar 25 '24 |
Option Exercise |
1.79 |
15,000 |
26,850 |
492,847 |
About Vaxcyte Inc
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
1.53%
3.38%
Cap:
|
Volume (24h):